JP6977029B2 - レット症候群を治療するためのプリドピジンの使用 - Google Patents
レット症候群を治療するためのプリドピジンの使用 Download PDFInfo
- Publication number
- JP6977029B2 JP6977029B2 JP2019514217A JP2019514217A JP6977029B2 JP 6977029 B2 JP6977029 B2 JP 6977029B2 JP 2019514217 A JP2019514217 A JP 2019514217A JP 2019514217 A JP2019514217 A JP 2019514217A JP 6977029 B2 JP6977029 B2 JP 6977029B2
- Authority
- JP
- Japan
- Prior art keywords
- predopidine
- subject
- use according
- administered
- mecp2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395854P | 2016-09-16 | 2016-09-16 | |
| US62/395,854 | 2016-09-16 | ||
| PCT/US2017/051803 WO2018053280A1 (en) | 2016-09-16 | 2017-09-15 | Use of pridopidine for treating rett syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532926A JP2019532926A (ja) | 2019-11-14 |
| JP2019532926A5 JP2019532926A5 (https=) | 2019-12-26 |
| JP6977029B2 true JP6977029B2 (ja) | 2021-12-08 |
Family
ID=61619744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514217A Active JP6977029B2 (ja) | 2016-09-16 | 2017-09-15 | レット症候群を治療するためのプリドピジンの使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3512506B1 (https=) |
| JP (1) | JP6977029B2 (https=) |
| CN (1) | CN109982686A (https=) |
| AU (1) | AU2017326013B2 (https=) |
| BR (1) | BR112019005040A2 (https=) |
| CA (1) | CA3036984C (https=) |
| DK (2) | DK3512506T3 (https=) |
| ES (2) | ES2909557T3 (https=) |
| HU (1) | HUE058314T2 (https=) |
| IL (1) | IL265342B2 (https=) |
| MX (1) | MX388845B (https=) |
| PL (2) | PL4005570T3 (https=) |
| WO (1) | WO2018053280A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| WO2018039475A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating dystonias |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| SG188298A1 (en) | 2010-09-03 | 2013-04-30 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| MX347209B (es) * | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| HK1206297A1 (en) | 2012-04-04 | 2016-01-08 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
| PE20161220A1 (es) * | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP4282479A3 (en) * | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| ES2909557T3 (es) | 2016-09-16 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Utilización de la pridopidina para el tratamiento del síndrome de Rett |
-
2017
- 2017-09-15 ES ES17851614T patent/ES2909557T3/es active Active
- 2017-09-15 HU HUE17851614A patent/HUE058314T2/hu unknown
- 2017-09-15 EP EP17851614.2A patent/EP3512506B1/en active Active
- 2017-09-15 BR BR112019005040A patent/BR112019005040A2/pt not_active Application Discontinuation
- 2017-09-15 WO PCT/US2017/051803 patent/WO2018053280A1/en not_active Ceased
- 2017-09-15 PL PL22150695.9T patent/PL4005570T3/pl unknown
- 2017-09-15 CA CA3036984A patent/CA3036984C/en active Active
- 2017-09-15 AU AU2017326013A patent/AU2017326013B2/en active Active
- 2017-09-15 DK DK17851614.2T patent/DK3512506T3/da active
- 2017-09-15 CN CN201780071045.XA patent/CN109982686A/zh active Pending
- 2017-09-15 PL PL17851614T patent/PL3512506T3/pl unknown
- 2017-09-15 MX MX2019003069A patent/MX388845B/es unknown
- 2017-09-15 ES ES22150695T patent/ES2986807T3/es active Active
- 2017-09-15 EP EP22150695.9A patent/EP4005570B1/en active Active
- 2017-09-15 DK DK22150695.9T patent/DK4005570T3/da active
- 2017-09-15 JP JP2019514217A patent/JP6977029B2/ja active Active
-
2019
- 2019-03-13 IL IL265342A patent/IL265342B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3512506T3 (pl) | 2022-05-30 |
| IL265342A (en) | 2019-05-30 |
| JP2019532926A (ja) | 2019-11-14 |
| EP4005570B1 (en) | 2024-05-15 |
| MX388845B (es) | 2025-03-20 |
| HUE058314T2 (hu) | 2022-07-28 |
| AU2017326013A1 (en) | 2019-04-11 |
| EP3512506A4 (en) | 2020-05-27 |
| CN109982686A (zh) | 2019-07-05 |
| ES2909557T3 (es) | 2022-05-09 |
| DK4005570T3 (da) | 2024-08-19 |
| PL4005570T3 (pl) | 2024-09-23 |
| BR112019005040A2 (pt) | 2019-07-16 |
| AU2017326013B2 (en) | 2020-12-24 |
| EP3512506B1 (en) | 2022-01-26 |
| CA3036984C (en) | 2023-07-18 |
| WO2018053280A1 (en) | 2018-03-22 |
| DK3512506T3 (da) | 2022-04-19 |
| ES2986807T3 (es) | 2024-11-12 |
| IL265342B2 (en) | 2023-06-01 |
| EP4005570A1 (en) | 2022-06-01 |
| EP3512506A1 (en) | 2019-07-24 |
| CA3036984A1 (en) | 2018-03-22 |
| MX2019003069A (es) | 2019-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6977029B2 (ja) | レット症候群を治療するためのプリドピジンの使用 | |
| US20200276136A1 (en) | Method of treating selected patient population experiencing dravet syndrome | |
| US20190247333A1 (en) | Method of reduction in convulsive seizure frequency | |
| KR20160037169A (ko) | 레트 증후군 및 그를 위한 치료 | |
| AU2024266870A1 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| BR112019010470A2 (pt) | métodos de realce de resposta imune com everolimo, dactolisib ou ambos | |
| Holmes et al. | Sex-split analysis of pathology and motor-behavioral outcomes in a mouse model of CLN8-Batten disease reveals an increased disease burden and trajectory in female Cln8 mnd mice | |
| US20240398778A1 (en) | Use of pridopidine for treating rett syndrome | |
| JP7744419B2 (ja) | レット症候群を治療するためのプリドピジンまたはその類似体の使用 | |
| CN108601772A (zh) | 用于治疗tdp-43蛋白质病的他克莫司 | |
| HK40009961B (en) | Use of pridopidine for treating rett syndrome | |
| Reddy et al. | Pharmacotherapy of Basal Ganglia Disorders: Parkinson Disease and Huntington Disease | |
| WO2025120480A1 (en) | Methods for treating subjects with autism spectrum disorder | |
| Litzenburger et al. | 32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191018 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191018 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200908 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210420 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210713 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211012 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211110 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6977029 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |